The NGS platforms market was dominated by Illumina in 2012, which accounted for the largest market share of 56%. Other companies with commercial platforms include Life Technologies (U.S.), 454 Roche (U.S.), and Pacific Biosciences (U.S.). The recently introduced Bench-top and NGS platforms will drive the market. Based on the steps in the NGS workflow, the overall NGS market has three major segments, namely, pre-sequencing, NGS platforms and services, and NGS data analysis, storage and management.
The raw sequencing data generated by today’s sequencers does not reflect on any meaningful information in itself. Also, open source tools for analyzing NGS data require adequate bioinformatics training. These factors open up huge opportunities for commercial NGS bioinformatics software, workbenches, and services, whose market is currently fragmented and has a relatively smaller size. Whole genome sequencing, targeted re-sequencing, de novo sequencing, RNA-Seq, ChIP-Seq and methyl-Seq are the major applications that use NGS data analysis tools and services. Key players like CLC bio (Denmark), Biomatters (New Zealand), Partek (U.S.), Genomatix (Germany), Knome (U.S.), and DNASTAR (U.S.) dominate this market space.
Next generation sequencing is set to revolutionize applied markets like diagnostics, drug discovery, biomarker discovery, personalized medicine, agriculture and animal research. Research institutes and government bodies contribute the highest to the end-user market of NGS; however, the adoption rate in hospitals will increase in the near future due to cost effectiveness, high throughput, and sensitivity.The NGS market will witness a whole new generation of sequencing platforms based on nanapore sequencing technology and fully integrated instruments that could perform all the NGS workflow steps.
Global DNA Sequencing
Copyright©2012 Vocus, Inc.
All rights reserved